The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.
An article from
Dive Brief
The company made the announcement after a new round of research results bolstered the case for the experimental medicine.
Published May 27, 2026
By
Apogee lands Blackstone $800M royalty deal to move Dupixent rival toward Phase 3
Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data - Apogee Therapeutics (NASDAQ:
ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
‘Dozens’ of treatments for chronic itch under investigation
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
Pipeline progress: Expanded therapeutic toolbox for cutaneous lupus is ‘imminent’
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
JAMA Neurology Publishes Phase 3 Data on D1 Receptor Antagonist Ecopipam in Tourette Syndrome
EU and US advisers split over AstraZeneca breast cancer drug
Apogee Therapeutics secures up to $800 million royalty deal with Blackstone Life Sciences to fund Phase 3 trials of eczema drug…
Apogee shares fell after announcing a $1.3 billion Blackstone financing deal alongside positive Phase 2 eczema drug results.
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
Two months after UCB revealed the success of Bimzelx in a head-to-head trial aga | Two months after UCB revealed the success of…
Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb;…
Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according…
